Walleye Capital’s Aerie Pharmaceuticals AERI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-6,000
Closed -$145K 1905
2019
Q4
$145K Sell
6,000
-22,500
-79% -$466K 0.01% 1254
2019
Q3
$548K Buy
+28,500
New +$653K 0.03% 703

Walleye Capital's AERI Position: Q4 2022 in Review

Walleye Capital sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 67,310 shares — an estimated $1.02M sold.

Walleye Capital first reported a position in AERI in Q2 2019 and held it in 7 quarters. The position peaked at $4.74M in Q2 2022. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.

  • Walleye Capital reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Walleye Capital sold 67,310 Aerie Pharmaceuticals shares in Q4 2022, an estimated $1.02M.
  • Walleye Capital first reported a position in Aerie Pharmaceuticals in Q2 2019 and held it in 7 quarters.
  • Walleye Capital's Aerie Pharmaceuticals position peaked at $4.74M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.

Based on Walleye Capital's 13F filing for Q4 2022, filed 14 Feb 2023.